Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptor

American Journal of Pathology

Volumn 155, Issue 4, 1999, Pages 1271-1279

  Chott, Andreas ^a,c   Sun, Zijie ^a,d   Morganstem, Daniel ^a   Pan, Jing ^a   Li, Tong ^a   Susani, Martin ^c   Mosberger, Isabella ^c   Upton, Melissa P ^b   Bubley, Glenn J ^a   Balk, Steven P ^a,b  

^a Division of Hematology and Oncology   (United States)

^b BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^c UNIVERSITY OF VIENNA   (Austria)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN TYROSINE KINASE; SOMATOMEDIN C RECEPTOR;

ARTICLE; BONE MARROW BIOPSY; BONE MARROW METASTASIS; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DOMAIN; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SIGNAL TRANSDUCTION;

EID: 0032877615     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9440(10)65229-7     Document Type: Article

References (49)

1. Haq M, Goltzman D, Tremblay G, Brodt P: Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. Cancer Res 1996, 52:4613-4619
2. Chackal-Roy M, Niemeyer C, Moore M, Zetter BR: Stimulation of human prostatic carcinoma cell growth by factors present in human bone marrow. J Clin Invest 1989, 84:43-50
3. Gleave M, Hsieh JT, Gao CA, von Eschenbach AC, Chung LW: Acceleration of human prostate cancer growth in vivo by factors produced by prostate and bone fibroblasts. Cancer Res 1991, 51: 3753-3761
4. Gleave ME, Hsieh JT, von Eschenbach AC, Chung LW: Prostate and bone fibroblasts induce human prostate cancer growth in vivo: implications for bidirectional tumor-stromal cell interaction in prostate carcinoma growth and metastasis. J Urol 1992, 147:1151-1159
5. Rossi MC, Zetter BR: Selective stimulation of prostatic carcinoma cell proliferation by transferrin. Proc Natl Acad Sci USA 1992, 89:6197-6201
6. Hsieh JT, Wu HC, Gleave ME, von Eschenbach AC, Chung LW: Autocrine regulation of prostate-specific antigen gene expression in a human prostatic cancer (LNCaP) subline. Cancer Res 1992, 53: 2852-2857
7. Pisters LL, Troncoso P, Zhau HE, Li W, von Eschenbach AC, Chung LW: c-met proto-oncogene expression in benign and malignant human prostate tissues. J Urol 1995, 154:293-298
8. Humphrey PA, Zhu X, Zarnegar R, Swanson, PE, Ratliff TL, Vollmer RT, Day ML: Hepatocyle growth factor and its receptor (c-MET) in prostatic carcinoma Am J Pathol 1995, 147:386-396
9. Sherwood ER, Lee C: Epidermal growth factor-related peptides and the epidermal growth factor receptor in normal and malignant prostate. World J Urol 1995, 13:290-296
10. Peehl DM, Cohen P, Rosenfeld RG: The insulin-like growth factor system in the prostate. World J Urol 1995, 13:306-311
11. Yan G, Fukabori Y, Nikolaropoulos S, Wang F, McKeehan WL: Heparin-binding keratinocyte growth factor is a candidate stromal-to-epithelial-cell andromedin. Mol Endocrinol 1992, 6:2123-2128
12. Peehl DM, Rubin JS: Keratinocyte growth factor: an androgen-regulated mediator of stromal-epithelial interactions in the prostate. World J Urol 1995, 13:312-317
13. Story MT: Regulation of prostate growth by fibroblast growth factors. World J Urol 1995, 13:297-305
14. Fudge K, Wang CY, Stearns ME: Immunohistochemistry analysis of platelet-derived growth factor A and B chains and platelet-derived growth factor alpha and beta receptor expression in benign prostatic hyperplasias and Gleason-graded human prostate adenocarcinomas. Mod Pathol 1994, 7:549-554
15. Fudge K, Bostwick DG, Stearns ME: Platelet-derived growth factor A and B chains and the alpha and beta receptors in prostatic intraepithelial neoplasia. Prostate 1996, 29:282-286
16. Pflug BR, Dionne C, Kaplan DR, Lynch J, Djakiew D: Expression of a Trk high affinity nerve growth factor receptor in the human prostate. Endocrinology 1995, 136:262-268
17. Wilks AF: Cloning members of protein-tyrosine kinase family using polymerase chain reaction. Methods Enzymol 1991, 200:533-546
18. Taplin ME, Bubley JG, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP: Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 1995, 332:1393-1398
19. Taplin ME, Bubley GJ, Ko Y-J, Small EJ, Upton M, Rajeshkumar B, Balk SP: Selection for androgen receptor mutations in prostate cancers treated with antiandrogen. Cancer Res 1999, 59:2511-2515
20. Horoszewisz JS, Leong SS, Kawanski E, Karr JP, Rosenthal H, Chu TM, Mirand EA, Murphy GP: LNCaP model of prostatic carcinoma. Cancer Res 1983, 43:1809-1818
21. Hanks SK, Quinn AM, Hunter T: The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science 1988, 241:42-52
22. Veldscholte J, Berrevoets CA, Ris-Stalpers C, Kuiper GG, Jenster G, Trapman J, Brinkmann AO, Mulder E: The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol 1992, 41:665-669
23. Thalmann GN, Anezinis PE, Chang SM, Zhau HE, Kim EE, Hopwood VL, Pathak S, von Eschenbach AC, Chung LW: Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. Cancer Res 1994, 54:2577-2581
24. Iwamura M, Sluss PM, Casamento JB, Cockett AT: Insulin-like growth factor I: action and receptor characterization in human prostate cancer cell lines. Prostate 1993, 22:243-252
25. Pietrzkowski Z, Mulholland G, Gomella L, Jameson BA, Wernicke D, Baserga R: Inhibition of growth of prostatic cancer cell lines by peptide analogues of insulin-like growth factor 1. Cancer Res 1993, 53:1102-1106
26. Kimura G, Kasuya J, Giannini S, Giannini S, Honda Y, Mohan S, Kawachi M, Akimoto M, Fujita-Yamaguchi Y: Insulin-like growth factor (IGF) system components in human prostatic cancer cell-lines: LN-CaP, DU145, and PC-3 cells. Int J Urol 1996, 3:39-46
27. Qiu Y, Robinson D, Pretlow TG, Kung HJ: Etk/Bmx, a tyrosine kinase with a pleckstrin-nomology domain, is an effector of phosphatidylinositol 3′-kinase and is involved in interleukin 6-induced neuroendocrine differentiation of prostate cancer cells. Proc Natl Acad Sci USA 1998, 95:3644-3649
28. Yan G, Fukabori Y, McBride G, Nikolaropolous S, McKeehan WL: Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy. Mol Cell Biol 1993, 13:4513-4522
29. Carstens RP, Eaton JV, Krigman HR, Walther PJ, Garcia-Blanco MA: Alternative splicing of fibroblast growth factor receptor 2 (FGF-R2) in human prostate cancer. Oncogene 1997, 15:3059-3065
30. Briscoe J, Guschin D, Muller M: Signal transduction: just another signalling pathway. Curr Biol 1994, 4:1033-1035
31. Schindler C, Darnell JE, Jr: Transcriptional responses to polypeptide ligands: the JAK-STAT pathway. Annu Rev Biochem 1995, 64:621-651
32. Robinson D, He F, Pretlow T, Kung HJ: A tyrosine kinase profile of prostate carcinoma. Proc Natl Acad Sci USA 1996, 93:5958-5962
33. Cantley LC, Neel BG: New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc Natl Acad Sci USA 1999, 96:4240-4245
34. Mantzoros CS, Tzonou A, Signorello LB, Stampfer M, Trichopoulos D, Adami HO: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br J Cancer 1997, 76:1115-1118
35. Chan JM, Stampfer MJ, Giovannucci E, Gann PH, Ma J, Wilkinson P, Hennekens CH, Pollak M: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science 1998, 279:563-566
36. Wolk A, Mantzoros CS, Andersson SO, Bergstrom R, Signorello LB, Lagiou P, Adami HO, Trichopoulos D: Insulin-like growth factor 1 and prostate cancer risk: a population-based, case-control study. J Natl Cancer Inst 1998, 90:911-915
37. Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler MH, Parsons R: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 1997, 275:1943-1947
38. Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, Langford LA, Baumgard ML, Hattier T, Davis T, Frye C, Hu R, Swedlund B, Teng DH, Tavtigian SV: Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 1997, 15:356-362
39. Cairns P, Okami K, Halachmi S, Halachmi N, Esteller M, Herman JG, Jen J, Isaacs WB, Bova GS, Sidransky D: Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res 1997, 57: 4997-5000
40. Pesche S, Latil A, Muzeau F, Cussenot O, Fournier G, Longy M, Eng C, Lidereau R: PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene 1998, 16:2879-2883
41. Whang YE, Wu X, Suzuki H, Reiter RE, Tran C, Vessella HL, Said JW, Isaacs WB, Sawyers CL: Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc Natl Acad Sci USA 1998, 95:5246-5250
42. Vlietstra RJ, van Alewijk DC, Hermans KG, van Steenbrugge GJ, Trapman J: Frequent inactivation of PTEN in prostate cancer cell lines and xenografts. Cancer Res 1998, 58:2720-2723
43. Long L, Rubin R, Baserga R, Brodt P: Loss of the metastatic phenotype in murine carcinoma cells expressing an antisense RNA to the insulin-like growth factor receptor. Cancer Res 1995, 55:1006-1009
44. Burfeind P, Chernicky CL, Rininsland F, Ilan J: Antisense RNA to the type I insulin-like growth factor receptor suppresses tumor growth and prevents invasion by rat prostate cancer cells in vivo. Proc Natl Acad Sci USA 1996, 93:7263-7268
45. Tennant MK, Thrasher JB, Twomey PA, Drivdahl RH, Birnbaum RS, Plymate SR: Protein and messenger ribonucleic acid (mRNA) for the type 1 insulin-like growth factor (IGF) receptor is decreased and IGF-II mRNA is increased in human prostate carcinoma compared to benign prostate epithelium. J Clin Endocrinol Metab 1996, 81:3774-3782
46. Plymate SR, Tennant M, Birnbaum RS, Thrasher JB, Chatta G, Ware JL. The effect on the insulin-like growth factor system in human prostate epithelial cells of immortalization and transformation by simian virus-40 T antigen. J Clin Endocrinol Metab 1996, 81:3709-3716
47. Plymate SR, Bae VL, Maddison L, Quinn LS, Ware JL: Reexpression of the type 1 insulin-like growth factor receptor inhibits the malignant phenotype of simian virus 40 T antigen immortalized human prostate epithelial cells. Endocrinology 1997, 138:1728-1735
48. Plymate SS, Bae VL, Maddison L, Quinn LS, Ware JL: Type-1 insulin-like growth factor receptor reexpression in the malignant phenotype of SV40-T-immortalized human prostate epithelial cells enhances apoptosis. Endocrine 1997, 7:119-124
49. Kaplan PJ, Mohan S, Cohen P, Foster BA, Greenberg NM: The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model Cancer Res 1999, 59:2203-2209